Abstract 172P
Background
Several inflammation-based markers were found to have a prognostic value in malignancies. Recent studies have reported that the preoperative neutrophil-to-lymphocyte ratio (NLR) is useful for prognostication in a variety of oncologic patients. We analyzed the NLR in determining Pancreatic neuroendocrine neoplasm (PanNEN) clinical outcomes after surgery.
Methods
We evaluated 132 consecutive cases of PanNEN who underwent surgery in Tohoku University Hospital between May 2001 and December 2018. Eight patients with synchronous hepatic metastasis, two patients with NEC, one patient with an active infection at blood sampling, and one patient with R2 noncurative resection were excluded from the study. 120 patients divided into two groups according to the values of NLR based on the receiver operator characteristic (ROC) curve. Differences of the characteristics between the two NLR groups (<3.84 vs. ≥3.84) were investigated with the chi-squared test and the Wilcoxon rank-sum test. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated by univariate or multivariate analyses using Cox’s proportional hazards model.
Results
The median age was 60 years old (range 12-88). In the WHO2017 histological grade, NET G1, G2, and G3 included 74, 44, and 2 cases, respectively. The median follow-up period was 52.9 months (range, 1-182). The NLR values distributed between 0.44 and 5.32 (average 1.92 ± 0.88). Five- and ten‐year RFS was 90.4% and 80.1%, respectively. Ten (8.3%) cases of relapse were observed. The site of recurrence was liver in nine patients and lymph node metastasis in one. NLR showed a significant correlation with RFS (median RFS time, 44.6 months (NLR ≥ 3.84) and not reached (NLR <3.84), p < 0.001). The multivariate analysis identified ki67 (≥3.4 HR 8.9; 95% CI 2.14 to 60.3; P = 0.002), and preoperative NLR (≥3.84 HR 7.7; 95% CI 1.63 to 30.1; P = 0.013) were an independent predictor of recurrence.
Conclusions
NLR could be a useful prognostic marker of the recurrence estimation after surgery and a handy objective screening tool for the host immune response in patients with PanNEN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract